An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.
OBJECTIVE
To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).


METHODS
A 63-year-old morbidly obese male polytrauma patient with PD and type 2 diabetes mellitus was admitted to our intensive care unit postoperatively. Enteral feeds were administered per nasogastric tube and provided 0.88 g /kg/day of protein based on ideal body weight (IBW). His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube. To achieve better glycemic control, his enteral feeds were changed to a formula that provided 1.8 g/kg/day of protein based on IBW. In the following 24 hours, the patient's mental status deteriorated and he was reintubated. He developed a high fever (40.5 degrees C), leukocytosis, elevated serum creatine kinase (CK) (480-1801 units/L), and acute renal impairment. His enteral nutrition was changed to decrease protein intake to 1.0 g/kg/day based on IBW and he was given bromocriptine 5 mg 3 times daily via nasogastric tube. Within 24 hours, the patient's mental status improved, his temperature and CK decreased, and his renal function began to improve; the values returned to baseline levels on the 18th day of admission.


CONCLUSIONS
Withdrawal or dose reduction of levodopa in patients with PD has been reported to precipitate NMLS, which is potentially fatal. Because dietary protein can decrease the absorp0tion of levodopa, a potential for an interaction between levodopa and enteral feedings exists, although published reports of such an interaction are limited. In this patient, the likelihood that a drug-nutrient interaction occurred between levodopa and enteral feedings is considered to be probable based on the Naranjo probability scale and the Horn Drug Interaction Probability Scale.


CONCLUSIONS
Health-care professionals should be aware of the interaction between levodopa and protein content of enteral nutrition to avoid the occurrence of NMLS in patients with PD.
Bonnici
André
A
McGill University Health Centre, Montreal, Quebec, Canada. andre.bonnici@muhc.mcgill.ca
Ruiner
Carola-Ellen
CE
St-Laurent
Lyne
L
Hornstein
David
D
D000978:Antiparkinson Agents / Q000009:adverse effects*; D002230:Carbidopa / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004750:Enteral Nutrition / Q000009:adverse effects*; D018565:Food-Drug Interactions; D006801:Humans; D007362:Intensive Care Units; D007902:Length of Stay; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D010300:Parkinson Disease / Q000188:drug therapy
D000978:Antiparkinson Agents; D007980:Levodopa; D002230:Carbidopa